利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.02 秒)

    Diphenyl imidazoles as potassium channel modulators
    4.
    发明授权
    Diphenyl imidazoles as potassium channel modulators 有权
    二苯基咪唑作为钾通道调节剂

    公开(公告)号：US06271249B1

    公开(公告)日：2001-08-07

    申请号：US09538520

    申请日：2000-03-29

    申请人： Jeffrey L. Romine ,  Scott W. Martin ,  Piyasena Hewawasam ,  Nicholas A. Meanwell ,  Valentin K. Gribkoff ,  John E. Starrett, Jr.

    发明人： Jeffrey L. Romine ,  Scott W. Martin ,  Piyasena Hewawasam ,  Nicholas A. Meanwell ,  Valentin K. Gribkoff ,  John E. Starrett, Jr.

    IPC分类号： A61K31402

    CPC分类号： C07D263/58 ,  C07D233/64 ,  C07D233/70 ,  C07D233/76 ,  C07D235/12 ,  C07D249/12 ,  C07D249/14 ,  C07D271/113 ,  C07D413/10

    摘要： Novel compounds of Formula 1 are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels: wherein “Het” is one of a select group of heterocyclic moieties; Z is independently for each occurrence selected from O or S; Ra, Rb and Rc each are independently selected from hydrogen, halogen, OH, CF3, NO2, or provided Rc is not hydrogen; and when Ra and Rb are hydrogen, Rc may be a heterocyclic moiety selected from the group consisting of imidazol-1-yl, morpholinomethyl, N-methylimidazol-2-yl, and pyridin-2-yl; Rd and Re each are independently selected from hydrogen, halogen, CF3, NO2 or imidazol-1-yl; m, n and p each are independently selected from an integer of 0 or 1; and Rf and Rg each are independently hydrogen; C1-4 alkyl; or Rf and Rg, taken together with the nitrogen atom to which they are attached, is a heterocyclic moiety selected from the group consisting of N-methylpiperazine, morpholine, thiomorpholine, N-benzylpiperazine and imidazolinone.

    摘要翻译： 式1的新型化合物可用于治疗对大电导钙激活钾通道的开放剂起反应的病症：其中“Het”是选择性杂环部分组之一; Z独立地选自O或S; R a，R b和R c各自独立地选自氢，卤素，OH，CF 3，NO 2，或提供的R c不是氢; 当R a和R b为氢时，R c可以是选自咪唑-1-基，吗啉代甲基，N-甲基咪唑-2-基和吡啶-2-基的杂环部分; Rd和Re各自独立地选自氢，卤素，CF 3，NO 2或咪唑-1-基; m，n和p各自独立地选自0或1的整数; Rf和Rg各自独立地为氢; C 1-4烷基 或R f和R g与它们所连接的氮原子一起是选自N-甲基哌嗪，吗啉，硫代吗啉，N-苄基哌嗪和咪唑啉酮的杂环部分。

    3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
    6.
    发明授权
    3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators 失效
    3-取代-4-芳基喹啉-2-酮衍生物作为钾通道调节剂

    公开(公告)号：US06184231B2

    公开(公告)日：2001-02-06

    申请号：US09452523

    申请日：1999-12-01

    申请人： Piyasena Hewawasam ,  John E. Starrett, Jr.

    发明人： Piyasena Hewawasam ,  John E. Starrett, Jr.

    IPC分类号： A61K314704

    CPC分类号： C07D215/227 ,  C07D215/54

    摘要： The present invention provides novel 3-substituted-4-arylquinolin-2-one derivatives having the general formula wherein R, R1, R2, R3, R4, R5, R6 and R7 are as defined herein, or a non-toxic pharmaceutically acceptable salt thereof which are modulators of the large conductance calcium-activated K+ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels.

    摘要翻译： 本发明提供了具有通式R，R 1，R 2，R 3，R 4，R 5，R 6和R 7如本文所定义的新的3-取代-4-芳基喹啉-2-酮衍生物或其无毒的药学上可接受的盐 其是大电导钙激活的K +通道的调节剂，并且可用于治疗对钾通道开放有反应的病症。

    N-substituted prodrugs of fluorooxindoles
    9.
    发明授权
    N-substituted prodrugs of fluorooxindoles 有权
    氟代吲哚的N-取代的前药

    公开(公告)号：US07169803B2

    公开(公告)日：2007-01-30

    申请号：US11074288

    申请日：2005-03-07

    申请人： John E. Starrett, Jr. ,  Omar D. Lopez ,  Piyasena Hewawasam ,  Min Ding

    发明人： John E. Starrett, Jr. ,  Omar D. Lopez ,  Piyasena Hewawasam ,  Min Ding

    IPC分类号： A61K31/405 ,  C07D209/34

    CPC分类号： C07D209/34 ,  C07D403/12

    摘要： The present invention provides novel N-substituted fluorooxindoles having the general Formula I wherein the wavy bond represents the racemate, the (R)-enantiomer or the (S)-enantiomer and m, n, p, q, A, B, D, Q, X, and Z are as defined below, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are responsive to the opening of potassium channels.

    摘要翻译： 本发明提供具有通式I的新型N-取代的氟代吲哚，其中波状键表示外消旋物，（R） - 对映体或（S） - 对映体，m，n，p，q，A，B，D， Q，X和Z如下所定义，或其无毒的药学上可接受的盐或溶剂化物，并且可用于治疗对钾通道开放有响应的病症。